imatinib mesylate has been researched along with Rupture in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bjerkehagen, B; Boye, K; Hompland, I; Hølmebakk, T; Stoldt, S | 1 |
Deneve, J; Gonzalez, RJ; Han, D | 1 |
Ballesteros, J; Pulido, EG; Riquelme, A; Vaz, MÁ | 1 |
1 review(s) available for imatinib mesylate and Rupture
Article | Year |
---|---|
Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Risk Factors; Rupture; Survival Rate | 2012 |
2 other study(ies) available for imatinib mesylate and Rupture
Article | Year |
---|---|
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Adult; Aged; Databases, Factual; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, University; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Norway; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rupture; Survival Analysis; Treatment Outcome | 2019 |
Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rupture; Treatment Outcome | 2012 |